NCT03204370 - Natural History of Atypical Morquio A Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

February 1, 2025

Study Completion Date

September 1, 2025

Conditions

Mucopolysaccharidosis IV A

Interventions

DRUG

Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM]

A subgroup of MPS4A patients will be treated by VIMIZIM drug, prescribed in usual care

Trial Locations (1)

Rheumatology department - Bordeaux University Hospital, Bordeaux